Ypsomed Holding AG · SIX:YPSN

Ypsomed — FY2021/22 Earnings Presentation

52 slides from Ypsomed's earnings presentation, May 25, 2022

  1. Slide 1: Ypsomed – Making life easier

    Ypsomed – Making life easier Zurich, 25 May 2022

  2. Slide 2: Disclaimer

    Disclaimer The information in this presentation constitutes neither an offer to sell nor an invitation to buy any securities. This presentation and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entit

  3. Slide 3: Making selfcare simpler and easier

    Making selfcare simpler and easier Improved therapy outcomes for chronic conditions 3 | Ypsomed Holding AG | Full-Year Results 2021/22

  4. Slide 4: Healthcare's biggest challenge – chronic conditions

    Healthcare’s biggest challenge – chronic conditions Selfcare is key for a better management of chronic conditions Turnover Group +90% The national per capita total cost of of every US healthcare dollar goes to chronic disease in the USA is treating people with chronic conditions1 11’201 USD2 80% 47%

  5. Slide 5: Non-adherence for chronic conditions a major issue

    Non-adherence for chronic conditions a major issue Smart self management improves therapy outcome  10 % of all hospitalisations could be saved through improved adherence  125,000 patients die in the USA due to lack of adherence to therapy  Non-adherence costs USD 290 billion annually in the U.S.

  6. Slide 6: Solutions for healthcare's biggest challenge

    Solutions for healthcare’s biggest challenge Ypsomed’s underlying future-oriented growth trends  Selfcare Improving quality of life, therapy adherence and enabling an affordable healthcare systems  Biologics Most new-generation drugs with complex active pharmaceutical ingredients have to be inject

  7. Slide 7: Ypsomed's strategy, growth drivers and purpose

    Ypsomed’s strategy, growth drivers and purpose Making life easier Innovation & Optimal Therapy Digitisation Digital Health Outcome Access & Biologics & Global Access to Expansion Biosimilars affordable Care Responsibility & Carbon Climate Change Engagement Net Zero & Integrity Technology Platforms &

  8. Slide 8: Ypsomed's strategy is sustainable

    Ypsomed’s strategy is sustainable Contributing positively to 13 of the 17 UN SDGs Innovation & Digital Health Access & Expansion Responsibility & Engagement Technology Platforms & Operational Excellence UN SDGs = United Nations Sustainable Development Goals 8 | Ypsomed Holding AG | Full-Year Results

  9. Slide 9: Figures & Business Development Financial Year 2021/22

    Figures & Business Development Financial Year 2021/22

  10. Slide 10: Highlights

    Highlights Innovation & Digital Health  YpsoPump®: Launch of AID with CamDiab and partnership with Abbott  Strategy in Digital Health with focus on fast access defined Access & Expansion  YpsoPump®: Project with Lilly and submission for FDA on track  Record 36 new project orders with existing an

  11. Slide 11: Key Figures

    Key Figures Sales growth Turnover Group Injection Systems +15 % +31 % mylife™ YpsoPump® EBIT CHF 28.6 Mio. End of April 2022 ~19’500 active users Net result CHF 23.1 Mio. 11 | Ypsomed Holding AG | Full-Year Results 2021/22

  12. Slide 12: Turnover growth of 15.2% for Ypsomed Group

    Turnover growth of 15.2 % for Ypsomed Group 12 | Ypsomed Holding AG | Full-Year Results 2021/22

  13. Slide 13: Delivery Systems strong revenue driver

    Delivery Systems strong revenue driver  Sales in Ypsomed Delivery Systems (YDS) segment rose by 22.7 % to CHF 259.0 million  In Ypsomed Diabetes Care (YDC) segment, turnover increased slightly by 5.5 % to CHF 187.5 million  Revenues in the segment Others increased strongly by 24.2 % to CHF 18.3 m

  14. Slide 14: Ypsomed Delivery System

    Ypsomed Delivery System  Recurring business model resulting in a reliable performance with deliveries for introduced products  Growth in new products for pens and autoinjectors  Strong performance in project business based on our large pipeline, fostering our future commercial sales  Continued s

  15. Slide 15: Turnover Ypsomed Delivery Systems

    Turnover Ypsomed Delivery Systems Growth of 31 % in Injection Systems  Sales growth of 30.6 % for Injection Systems in 2021/22  Main contributors are our platform families UnoPen™ and YpsoMate®  Followed by our reusable ServoPen®  Increase of 31.4 % for project revenues  Sales contribution of C

  16. Slide 16: Turnover Ypsomed Diabetes Care

    Turnover Ypsomed Diabetes Care 5.5 % growth mainly based on development services  Development services for infusion pump partners as main contributor  Commercial sales for YpsoPump® stagnated  Revenues of test strips and DiaExpert declined slightly  Pen needles sales down 5.0 % due to developmen

  17. Slide 17: Ypsomed Diabetes Care

    Ypsomed Diabetes Care  Recurring business for consumables such as infusion sets robust  Due to late integration of CGM and missing Loop-features we are not yet on track with the adoption of new YpsoPump® users  We focus on: – fast implementation of the mylife™ Loop program with our partner CamDia

  18. Slide 18: New Senior Vice President Diabetes Care Sébastien Delarive

    New Senior Vice President Diabetes Care Sébastien Delarive  More than 25 years of experience from various positions in international marketing, sales, product lifecycle and general management in the pharmaceutical and medtech sectors  In his most recent position as of Head of Europe he was respons

  19. Slide 19: EBIT development 2020/21 to 2021/22

    EBIT development 2020/21 to 2021/22 Ypsomed Group 19 | Ypsomed Holding AG | Full-Year Results 2021/22

  20. Slide 20: Unchanged positive fundamentals for Ypsomed

    Unchanged positive fundamentals for Ypsomed Executing our strategy  Our products are vital for people  We prepare to extend our business with chronic conditions, resulting in a model with digital services recurring business model  We execute our sustainable  In compliance with international stra

  21. Slide 21: Ypsomed creating 209 new jobs in 24 months

    Ypsomed creating 209 new jobs in 24 months 161 of them in Switzerland 21 | Ypsomed Holding AG | Full-Year Results 2021/22

  22. Slide 22: Continued high investments to support future growth

    Continued high investments to support future growth 22 | Ypsomed Holding AG | Full-Year Results 2021/22

  23. Slide 23: Planned capital increase to support projected growth – Offering

    Planned capital increase to support projected growth Offering  Offering up to 1 million new registered  Subscription and book building shares period expected to last from 16 to 23 June 2022, noon  Rights offering to all eligible holders of existing shares  New shares eligible for dividend paymen

  24. Slide 24: Planned capital increase – Use of proceeds

    Planned capital increase to support projected growth Use of proceeds  Upfront investments in the accelerated manufacturing expansion, primarily for Injection Systems  Financial flexibility to push ahead with digitisation  Reduction of the loan of its major shareholder (Verrechnungsliberierung) 24

  25. Slide 25: Main assumptions for the Financial Year 2022/23

    Main assumptions for the Financial Year 2022/23  Stable performance of commercial  Launch of mylife™ CamAPS in deliveries for introduced products Germany, Austria and Switzerland in and in established markets H1 2022  Covid-19 and FDA backlog related  Roll-out in rest of Europe in H2 2022 delay

  26. Slide 26: Outlook for the Financial Years 2022/23 and 2023/24

    Outlook for the Financial Years 2022/23 and 2023/24  For the financial year 2022/23, Ypsomed expects sales growth at Group level to be in the same range as in the previous financial year.  For the financial year 2022/23, Ypsomed expects a further significant improvement in the operating profit (EB

  27. Slide 27: Changes in the Board of Directors at Ypsomed

    Changes in the Board of Directors at Ypsomed Chairman Willy Michel will hand over to Gilbert Achermann 27 | Ypsomed Holding AG | Full-Year Results 2021/22

  28. Slide 28: Deeper dive into our four strategic pillars

    Deeper dive into our four strategic pillars Innovation & Digital Health Access & Expansion Responsibility & Engagement Technology Platforms & Operational Excellence 28 | Ypsomed Holding AG | Full-Year Results 2021/22

  29. Slide 29: Innovation & Digital Health

    Innovation & Digital Health We invest above average in research and develop- ment. When developing new solutions, the focus is on added value for those affected, the customers and society.

  30. Slide 30: Introducing AID with CamDiab, including Dexcom G6

    Introducing AID with CamDiab, including Dexcom G6 Changing the paradigm with CamAPS FX  Connecting mylife™ YpsoPump® to mylife™ Camps® FX Android app  Integrating a unique, adaptive and responsive control algorithm  Personalised and self-learning to adapt to changing insulin needs  Bolus directl

  31. Slide 31: Hybrid closed-loop in (very young) children and beyond

    Hybrid closed-loop in (very young) children and beyond Industry symposium supported by Ypsomed at ATTD Professor Roman Hovorka, Director CamDiab Ltd and David Bosshard, Vice President Product Management Ypsomed Diabetes Care 31 | Ypsomed Holding AG | Full-Year Results 2021/22

  32. Slide 32: Successful introduction of mylife Loop in Germany

    Successful introduction of mylife™ Loop™ in Germany 32 | Ypsomed Holding AG | Full-Year Results 2021/22

  33. Slide 33: Partnering with Abbott

    Partnering with Abbott Automated insulin delivery with Abbott’s Freestyle Libre 3  Ypsomed, Abbott and CamDiab partner to develop and commercialize a new AID system  Connecting Ypsomed’s mylife™ YpsoPump® with Abbott’s FreeStyle Libre® 3 sensor and CamDiab’s CamAPS® FX app  The initial focus will

  34. Slide 34: YpsoMate On – Pharmapack Exhibitor Innovation Award 2022

    YpsoMate® On Pharmapack Exhibitor Innovation Award 2022  YpsoMate® On is the world’s first pre- filled autoinjector with integrated connectivity  The injection data is automatically transferred to the user's therapy management app and the associated cloud  It has been developed in line with our n

  35. Slide 35: Advancing SmartServices to an integrated solution

    Advancing SmartServices™ to an integrated solution Adherence as a service business model 4 Therapy Management APIs Device Management & 3 SDKs Therapy Monitoring 2 Smart Device 1 Self administration Device 35 | Ypsomed Holding AG | Full-Year Results 2021/22

  36. Slide 36: Digital Health evolving to evidence-based solutions

    Digital Health evolving to evidence-based solutions  Shift from product differentiation to improving therapy outcomes  Becoming more therapy specific  Evidence-based and clinically validated  Patients to be actively involved  Increase of therapy efficacy through combination of traditional treat

  37. Slide 37: Opening of our digital development hub in Barcelona

    Opening of our digital development hub in Barcelona 37 | Ypsomed Holding AG | Full-Year Results 2021/22

  38. Slide 38: Access & Expansion

    Access & Expansion We improve medical care worldwide. To make life easier for those affected, we want to serve the widest possible range of disease areas.

  39. Slide 39: Commercial launch of the YpsoMate 2.25 Pro

    Commercial launch of the YpsoMate 2.25 Pro  Injection volumes up to 2.25 ml  Innovative drive system for constant force  Suitable for a large range of viscosities  First commercial deliveries serving the disease area of atopic dermatitis as an additional indication 39 | Ypsomed Holding AG | Full

  40. Slide 40: Ypsomed and SCHOTT driving large-volume injections

    Ypsomed and SCHOTT driving large-volume injections YpsoDose® and cartriQ®  New and established drugs are being formulated for subcutaneous administration to enhance the quality of life and to reduce the burden for healthcare systems  Over the last years, much of the demand for new device innovatio

  41. Slide 41: Current disease areas of commercialised platforms

    Current disease areas of commercialised platforms Pens Auto- and patch-injectors  Diabetes (Insulin, GLP-1)  Asthma  Osteoporosis (PTH)  Migraine  Growth disorders (hGH)  Multiple sclerosis  Fertility  Sexual dysfunction  Parkinson  Rheumatoid arthritis  Psoriasis  Dermatitis 41 | Ypsome

  42. Slide 42: Potential future disease areas

    Potential future disease areas Pens Auto- and patch-injectors  Diabetes (Insulin, GLP-1)  Asthma  Osteoporosis (PTH)  Migraine  Growth disorders (hGH)  Multiple sclerosis  Fertility  Sexual dysfunction  Parkinson  Rheumatoid arthritis  Rheumatoid arthritis  Psoriasis  Bullous pemphigoid

  43. Slide 43: Platforms & Operational Excellence

    Platforms & Operational Excellence With our platform approach and scalable capacities, we are able to provide products quickly and reliably. We operate according to the principles of lean manage- ment and highly automated processes to expand our cost leadership.

  44. Slide 44: Products built on platforms

    Products built on platforms Fast, flexible and cost efficient 44 | Ypsomed Holding AG | Full-Year Results 2021/22

  45. Slide 45: Established platform device offering

    Established platform device offering  Reduction of risks and shortened “time-to-market“  Technological leadership due to consistent ongoing modular evolution  Cost leadership due to scaling effects and scalable automated manufacturing 45 | Ypsomed Holding AG | Full-Year Results 2021/22

  46. Slide 46: Evolution of the YpsoMate autoinjector portfolio

    Evolution of the YpsoMate™ autoinjector portfolio 46 | Ypsomed Holding AG | Full-Year Results 2021/22

  47. Slide 47: Planning further manufacturing capacity expansion

    Planning further manufacturing capacity expansion Global expansion for regional supply chains  Accelerated expansion of Schwerin manufacturing site, with plan to build extension Hall D in 2023, adding another 4’000 m2 to the existing 24’000 m2  Deglobalisation means strong focus on the development

  48. Slide 48: Responsibility & Engagement

    Responsibility & Engagement We are committed to our employees, partners and society. We support the circular economy and reduce our carbon footprint.

  49. Slide 49: Our long-term plan to Net Zero

    Our long-term plan to Net Zero  By 2030, net zero operational CO2 emissions (Scope 1 and 2)  By 2030, a selection of our products meet net zero CO2 emissions across their individual value chain (Scope 1 to 3)  By 2040 at the latest, net zero CO2 emissions across our entire value chain (Scope 1 to

  50. Slide 50: Developing specific CO2 reduction targets

    Developing specific CO2 reduction targets Principles defined  Reduction first  Substitution and circulation involving our partners and suppliers  Compensation will be necessary  Already building a portfolio of compensation projects that – must be internationally certified – contribute positively

  51. Slide 51: Partnerships and sustainability standards

    Partnerships and sustainability standards Alliance to Zero Science Based Targets initiative Circular Economy Switzerland Verband für nachhaltiges Wirtschaften Swiss Cleantech CDP Climate disclosure project GRI Global Reporting Initiative 51 | Ypsomed Holding AG | Full-Year Results 2021/22

  52. Slide 52: Thank you.

    Thank you.

Ypsomed Holding — FY2021/22 Earnings Presentation on 6ix